Imunomoduliuojančio gydymo įtaka kognityvinių funkcijų sutrikimams, sergant IS: klinikinių tyrimų apžvalga.

Multiple sclerosis (MS) is an inflammatory demyelinating disorder of central nervous system that is the major course of the disability of young adults. Cogiivim pairment can occur even in early stages of MS and also in clinically isolated syndrome (CIS). As disease modifying drugs (DMD) can at ten u ate inflammatory processes and prevent brain atrophy, they may also have positive benefits oncognitivedys function in MS patients. Clinical trials demonstrate that interferon beta and natalizumab positively affect cognitive functions in MS patients. Most patients with relapsing multiple sclerosis had stable cognitive performance during 10 years of pro spective evaluation, some of which may be related to the therapeutic effect of glatirameracetate. There is clear evidence that early DMD treatment has positive effect on cognitive functions, until clinically isolated syndrome has not converted to definite MS. Immunosupressants (mitoxantrone and cyclophosphamide) can also positively affect cognitive functions in MS. Further studies are needed for de tailed evaluation of DMD effect on cognitive dysfunction in MS. [ABSTRACT FROM AUTHOR]